![Global Venous Thromboembolism Treatment Market by Device (Thrombectomy, Inferior Vena Cava Filter [Retrievable, Permanent], Stockings, Compression Pump) Application (DVT, Pulmonary Embolism) End User (Hospital, Ambulatory Care Center) - Forecast to 2030- Product Image](http://www.researchandmarkets.com/product_images/12604/12604696_500px_jpg/global_venous_thromboembolism_treatment_market.jpg)
The global venous thromboembolism treatment market is projected to reach $4.40 billion by 2030, at a CAGR of 7.2% from 2023 to 2030.
After conducting an extensive primary and secondary study and an in-depth analysis of the market scenario, this report offers insights into the key drivers, constraints, challenges, and opportunities within the venous thromboembolism treatment market.
The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the key factors driving the growth of the venous thromboembolism treatment market. Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.
However, instances of product failure and product recalls may restrain the market’s growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.
Among the devices covered in this report, in 2023, the thrombectomy devices segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and launches of new thrombectomy devices.
Among the applications covered in this report, in 2023, the deep vein thrombosis segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of obesity, a growing geriatric population, rising cases of deep vein thrombosis due to lifestyle-related diseases, excessive alcohol consumption, and heightened awareness of DVT.
Among the end users covered in this report, in 2023, the hospitals segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals. The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.
An in-depth analysis of the geographical scenario of the global venous thromboembolism treatment market provides detailed qualitative and quantitative insights into the five major geographies: North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India), Latin America, and the Middle East & Africa.
In 2023, North America is expected to account for the largest share of the global venous thromboembolism treatment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific is slated to register the largest CAGR during the forecast period. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism.
The key players operating in the global venous thromboembolism treatment market are ALN Implants chirurgicaux (ALN Surgical Implants) (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.).
After conducting an extensive primary and secondary study and an in-depth analysis of the market scenario, this report offers insights into the key drivers, constraints, challenges, and opportunities within the venous thromboembolism treatment market.
The high prevalence of venous thromboembolism, rising incidence of cancer, growing prevalence of secondary risk factors such as diabetes and obesity, increase in orthopedic surgical procedures, and the rising demand for minimally invasive treatment procedures are the key factors driving the growth of the venous thromboembolism treatment market. Furthermore, the growing accessibility and affordability of treatment options, advancements in VTE diagnosis and treatment methods, and the market expansion in emerging economies are expected to create market growth opportunities.
However, instances of product failure and product recalls may restrain the market’s growth. Additionally, lack of awareness about venous thromboembolism and increasing awareness of probable side effects of compression garments are major challenges for market growth.
Among the devices covered in this report, in 2023, the thrombectomy devices segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and launches of new thrombectomy devices.
Among the applications covered in this report, in 2023, the deep vein thrombosis segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share of this segment is attributed to the increasing prevalence of obesity, a growing geriatric population, rising cases of deep vein thrombosis due to lifestyle-related diseases, excessive alcohol consumption, and heightened awareness of DVT.
Among the end users covered in this report, in 2023, the hospitals segment is expected to account for the largest share of the venous thromboembolism treatment market. The large market share is attributed to the increasing prevalence of venous thromboembolism, the rising number of hospitals and clinics, the presence of highly skilled professionals, and the high purchasing power of hospitals. The easy accessibility to hospitals, coupled with a large patient population seeking comprehensive healthcare services, including diagnosis, treatment, and surgeries at a single location, also contributes to the significant market share of this segment.
An in-depth analysis of the geographical scenario of the global venous thromboembolism treatment market provides detailed qualitative and quantitative insights into the five major geographies: North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India), Latin America, and the Middle East & Africa.
In 2023, North America is expected to account for the largest share of the global venous thromboembolism treatment market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific is slated to register the largest CAGR during the forecast period. The growth of this regional market can be attributed to factors such as the growing prevalence of chronic diseases, the increasing number of people living sedentary lifestyles, growing health expenditures, supportive government initiatives aimed at improving healthcare infrastructure, and rising awareness regarding venous thromboembolism.
The key players operating in the global venous thromboembolism treatment market are ALN Implants chirurgicaux (ALN Surgical Implants) (France), AngioDynamics, Inc. (U.S.), Argon Medical Devices, Inc. (U.S.), ArjoHuntleigh AB (Sweden), Boston Scientific Corporation (U.S.), Cardinal Health, Inc. (U.S.), Cook Group Incorporated (U.S.), Koninklijke Philips N.V. (Netherlands), DS MAREF Co., LTD (South Korea), Enovis Corporation (U.S.), LifeTech Scientific Corporation (China), Medtronic plc (Ireland), and Stryker Corporation (U.S.).
Scope of the Report:
Venous Thromboembolism Treatment Market Assessment - by Device
- Thrombectomy Devices
- Inferior Vena Cava Filters
- Retrievable Filters
- Permanent Filters
- Stockings
- Compression Pumps
- Other Devices & Accessories
Venous Thromboembolism Treatment Market Assessment - by Application
- Deep Vein Thrombosis
- Pulmonary Embolism
Venous Thromboembolism Treatment Market Assessment - by End User
- Hospitals
- Ambulatory Care Centers
- Other End Users
Venous Thromboembolism Treatment Market Assessment - by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Venous Thromboembolism Treatment Market Assessment - by Device
6. Venous Thromboembolism Treatment Market Assessment - by Application
7. Venous Thromboembolism Treatment Market Assessment - by End User
8. Venous Thromboembolism Treatment Market Assessment - by Geography
9. Competition Analysis
10. Company Profiles
11. Appendix
List of Tables
List of Figures
Companies Mentioned
- ALN Implants chirurgicaux (ALN Surgical Implants) (France)
- AngioDynamics Inc. (U.S.)
- Argon Medical Devices Inc. (U.S.)
- ArjoHuntleigh AB (Sweden)
- Boston Scientific Corporation (U.S.)
- Cardinal Health Inc. (U.S.)
- Cook Group Incorporated (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- DS MAREF Co. Ltd (South Korea)
- Enovis Corporation (U.S.)
- LifeTech Scientific Corporation (China)
- Medtronic plc (Ireland)
- Stryker Corporation (U.S.)
